![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1174-5886
Source: Drugs in R&D, Vol.4, Iss.2, 2003-01, pp. : 115-118
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By de Boer T. Otjens D. Muntendam A. Meulman E. van Oostijen M. Ensing K.
Journal of Pharmaceutical and Biomedical Analysis, Vol. 34, Iss. 3, 2004-02 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
-Galactosidase replacement therapy in Fabry's disease
Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sevelamer [`Renagel'; Genzyme General] has received marketing approval in Brazil.
Inpharma, Vol. 1, Iss. 1302, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Agalsidase Beta: A Review of its Use in the Management of Fabry Disease
By Keating Gillian M. Simpson Dene
Drugs, Vol. 67, Iss. 3, 2007-01 ,pp. :